If you've searched for the tryptophan supplement ban 2005 lifted, you've probably encountered a confusing timeline.
Some accounts say tryptophan was banned in 1989 and returned in 2005. Others say the FDA loosened restrictions in 2001. Still others describe 2005 as the year the FDA finally allowed tryptophan supplements back into the United States.
The reality is more nuanced.
The U.S. regulatory history of L-tryptophan stretches from a serious 1989 outbreak of eosinophilia-myalgia syndrome, or EMS, through years of restrictions, regulatory reassessment, and an eventual cancellation of the FDA import alert in 2005.
The distinction matters because 2005 was not simply the date the FDA decided that tryptophan was safe again. Restrictions had already changed earlier. What happened in 2005 was particularly important because the FDA canceled the import alert that had effectively kept many foreign sources of L-tryptophan out of the U.S. market.
That history helps explain why modern consumers may find L-tryptophan products on the market today even though the ingredient is closely associated with one of the most significant supplement-related health scares in U.S. history.
This article explains what happened, why the original restriction lasted so long, what changed between 1989 and 2005, and what consumers should understand about the difference between L-tryptophan itself and the contaminated products associated with the 1989 outbreak.
The Short Answer: What Changed in 2005?
The simplest answer is this:
In 2005, the FDA canceled its import alert for L-tryptophan after determining that there was insufficient evidence to continue automatically detaining imported L-tryptophan without physical examination.
That decision effectively reopened the U.S. market to imported L-tryptophan, including material intended for dietary supplements.
The change followed years of investigation into the 1989 EMS outbreak and a growing understanding that the problem was associated with contaminated L-tryptophan from a particular manufacturing process rather than simply the existence of L-tryptophan as an amino acid.
But it is important not to oversimplify the story.
The FDA did not announce in 2005 that every tryptophan product was automatically safe. Nor did the agency create a special blanket category in which all “pharmaceutical-grade tryptophan” was preapproved for consumers.
Instead, the regulatory landscape moved toward allowing L-tryptophan to enter the market under the ordinary requirements applicable to regulated products.
That distinction is one of the most important facts in the entire tryptophan supplement regulatory history.
A Timeline of the Tryptophan Supplement Restrictions
Understanding the timeline makes the 2005 change much easier to understand.
1989: EMS outbreak emerges
In 1989, physicians and public-health investigators began identifying cases of a serious condition called eosinophilia-myalgia syndrome.
The illness involved severe muscle pain and elevated eosinophils, a type of white blood cell. Some patients developed neurological, skin, and connective-tissue complications.
Investigators found a striking association between the outbreak and L-tryptophan-containing dietary supplements.
The FDA responded with a nationwide recall involving over-the-counter dietary supplements containing 100 milligrams or more of L-tryptophan. By 1990, more than 1,500 EMS cases had been reported, including dozens of deaths.
1990: Import restrictions take hold
In March 1990, the FDA issued an import alert covering L-tryptophan.
An import alert allows the FDA to detain certain products at the border without physically examining every shipment. In practical terms, the restriction made it extremely difficult for many foreign sources of L-tryptophan to enter the U.S. market.
This is why the commonly used phrase “tryptophan ban” can be misleading.
The regulatory history was not simply a single law passed in 1989 saying, “tryptophan is illegal.” Rather, the FDA used recalls, restrictions, and import controls that effectively removed ordinary L-tryptophan supplements from widespread U.S. availability.
2001: Restrictions begin to loosen
The next major milestone came in 2001.
The FDA issued an information paper explaining its position on L-tryptophan and 5-HTP. By then, the agency had loosened restrictions on marketing L-tryptophan, although significant import restrictions remained in place.
This is an important date because it means the statement “tryptophan was banned for 16 years” is a useful shorthand, but not a perfect description of the regulatory history.
The market was not simply frozen from one day in 1989 until one day in 2005.
Instead, the restrictions changed over time.
2005: Import alert is canceled
In 2005, the FDA canceled the L-tryptophan import alert.
This was the major change that allowed imported L-tryptophan to re-enter the U.S. market without being automatically detained under the old alert. Contemporary summaries of the FDA action identify the cancellation as occurring in 2005 after the agency concluded there was insufficient evidence to continue detention without physical examination of foreign-source L-tryptophan.
That is the key event behind the phrase tryptophan supplement ban 2005 lifted.
What Was Eosinophilia-Myalgia Syndrome?
To understand why regulators reacted so strongly, it helps to understand EMS.
Eosinophilia-myalgia syndrome is a rare multisystem illness associated with severe muscle pain and elevated eosinophils. It can involve the muscles, nerves, fascia, and skin.
The 1989 outbreak was unusual because a large number of people developed similar symptoms within a relatively short period.
Early investigations found an unusually strong association with L-tryptophan-containing products.
One case-control investigation found that all 11 cases studied had used L-tryptophan-containing products, compared with only two of the matched controls. Those findings contributed to the decision to remove the products from the market.
The symptoms associated with EMS were not the kind of mild side effects normally discussed when people talk about dietary supplements.
Reported clinical features could include:
- Severe or disabling muscle pain
- Muscle weakness
- Fatigue
- Elevated eosinophil counts
- Nerve-related symptoms
- Skin thickening or hardening
- Swelling
- Breathing-related symptoms
- Connective-tissue involvement
The condition could also persist after the original exposure.
That severity explains why regulators did not simply treat the outbreak as an ordinary supplement-quality complaint.
Was L-Tryptophan Itself the Problem?
This is where the story becomes particularly interesting.
The investigation eventually focused on L-tryptophan produced by Showa Denko, a Japanese manufacturer.
Researchers found that the implicated material was associated with changes in the manufacturing process and the presence of impurities.
The important takeaway is that the outbreak was linked to a particular contaminated or altered supply of L-tryptophan rather than establishing that naturally occurring L-tryptophan itself was inherently capable of causing EMS.
Investigations identified multiple impurities in the implicated material. One compound that received considerable attention was known as EBT, or 1,1'-ethylidenebis-L-tryptophan.
However, the science became more complicated than simply identifying one contaminant and declaring the case closed.
Later research identified multiple compounds associated with the implicated material, and the precise mechanism responsible for EMS has remained uncertain. Researchers have continued to investigate how impurities, manufacturing conditions, individual susceptibility, and other factors may have interacted.
That nuance matters.
It would be inaccurate to say that scientists definitively proved one single contaminant was solely responsible for every case of EMS.
A more accurate description is that the outbreak was strongly associated with L-tryptophan produced by a particular manufacturer, and the investigation uncovered manufacturing-related impurities and process changes that became central to understanding the event.
How Manufacturing Changes Turned Into a Public-Health Crisis
The 1989 event is one of the clearest historical examples of why manufacturing quality can matter as much as the identity of an ingredient.
L-tryptophan is an amino acid. The molecule itself was not suddenly invented in 1989.
What changed was how large quantities were being produced.
By the 1980s, fermentation methods had made it possible to manufacture tryptophan at much greater scale. Investigators eventually traced the EMS-associated products to L-tryptophan made by a single Japanese manufacturer using a changed production process.
That distinction is essential for understanding the FDA's response.
Imagine two batches of the same chemical:
Batch A: Produced consistently, purified appropriately, and tested for relevant contaminants.
Batch B: Produced using a changed process that introduces unexpected byproducts or impurities.
On a label, both may simply say “L-tryptophan.”
From a manufacturing-quality perspective, they are not necessarily equivalent.
The 1989 outbreak demonstrated the consequences of that difference on a large scale.
Why Did the Restriction Last So Long?
One of the most common questions about the tryptophan FDA restriction timeline is why it took so many years to reverse.
There was no single reason.
Several factors made the regulatory situation unusually difficult.
1. The health consequences were serious
The initial outbreak involved more than 1,500 reported cases and numerous deaths.
When a supplement ingredient is associated with a serious, unexplained illness affecting people across multiple states, regulators have a strong incentive to act conservatively.
2. The exact cause was not immediately clear
At first, investigators knew there was a strong connection between L-tryptophan products and EMS.
But identifying the precise causal mechanism was much harder.
Was the problem the amino acid?
Was it a contaminant?
Was it multiple contaminants?
Was it the manufacturing process?
Were some consumers genetically or biologically more susceptible?
Those questions could not be answered overnight.
3. The manufacturing process mattered
The investigation increasingly pointed toward a specific manufacturer and changes in production.
That created a difficult regulatory problem.
Even if one source was responsible for the outbreak, regulators still needed confidence that other manufacturers could produce L-tryptophan without recreating the same problem.
4. Import controls were easier to maintain than remove
An import alert gives regulators a practical way to control a product associated with a known safety event.
Removing that restriction requires a different level of confidence.
The question becomes:
Is there enough evidence to justify allowing the product back into ordinary commerce?
That is a much more consequential decision than simply continuing to restrict it.
What Exactly Changed in 2005?
The phrase “2005 pharmaceutical grade tryptophan” appears frequently in searches about this subject, but it can create a misleading impression.
The 2005 development was fundamentally about the FDA import alert, not a new universal FDA approval for all pharmaceutical-grade tryptophan.
The FDA canceled the import alert because it no longer believed there was sufficient evidence to justify automatically detaining foreign-source L-tryptophan without physical examination.
That distinction has several practical implications.
It was not a declaration that all tryptophan products were identical
Manufacturing source still matters.
It was not a blanket guarantee of safety
Removing an import alert does not mean that every product containing the ingredient is automatically safe or compliant.
It did not eliminate FDA oversight
Imported products remain subject to applicable federal requirements. FDA import controls can still be used when products or manufacturers present compliance concerns.
It reopened the market
The most immediate practical effect was that L-tryptophan intended for dietary supplements could once again be imported into the United States without being automatically detained under the canceled alert.
That is why 2005 is such an important date in the tryptophan market return conditions.
Was Tryptophan Completely Banned for 16 Years?
Not exactly.
This is one of the most important distinctions to understand.
The phrase “16-year tryptophan ban” usually refers to the period between the 1989 outbreak and the 2005 lifting of the import restriction.
But the actual regulatory history involved multiple stages.
The FDA's initial action in 1989 included a nationwide recall of over-the-counter supplements containing significant amounts of L-tryptophan. In 1990, the FDA prohibited importation through an import alert. By 2001, the agency had loosened some marketing restrictions, but the import restriction remained until 2005.
So a better way to describe the timeline is:
1989: Major U.S. recall and restriction following EMS outbreak.
1990: L-tryptophan import alert effectively removes many foreign sources from the U.S. market.
2001: FDA loosens restrictions on marketing, while import restrictions continue.
2005: FDA cancels the L-tryptophan import alert.
This is more accurate than saying that nothing changed between 1989 and 2005.
Did the FDA Approve Tryptophan Again in 2005?
No. The 2005 action should not be described as a blanket FDA approval of tryptophan supplements.
Instead, the FDA canceled the import alert that had restricted foreign-source L-tryptophan.
This distinction is especially important because dietary supplements and pharmaceutical drugs operate under different regulatory frameworks.
A dietary supplement does not become an FDA-approved drug simply because its ingredient can legally be sold.
Likewise, “pharmaceutical grade” is not itself a magic regulatory designation that means a product has received FDA approval.
For consumers, the more useful question is not simply whether a label says “pharmaceutical grade.”
The useful questions are:
- Who manufactured the ingredient?
- Where was it manufactured?
- What quality controls were used?
- What testing was performed?
- How is the finished product tested?
- Does the manufacturer follow applicable quality requirements?
- Is there credible documentation of identity and purity?
Those questions are much closer to the heart of the lesson from the 1989 outbreak.
What Does “Pharmaceutical Grade” Actually Mean?
The phrase “pharmaceutical grade tryptophan” sounds reassuring, but shoppers should be careful with marketing language.
“Pharmaceutical grade” can be used commercially to communicate that an ingredient is made to a high standard, but consumers should not assume that the phrase by itself means:
- FDA-approved
- Prescription-only
- Clinically proven
- Risk-free
- Superior to every other source
- Free of every possible contaminant
Quality depends on actual manufacturing and testing practices.
The 1989 EMS crisis demonstrated why ingredient purity cannot be judged solely from the ingredient name printed on a bottle.
Two products can contain the same nominal ingredient while differing in source, manufacturing process, purification, testing, storage, and quality control.
The Role of Manufacturing Oversight in the Market's Return
The most important lesson from the tryptophan supplement regulatory history may be that manufacturing oversight matters.
The 1989 crisis was not simply a story about consumers taking too much of an amino acid.
It was a story about an ingredient entering the marketplace with unexpected impurities associated with a manufacturing process.
That changes the way the safety question should be approached.
Instead of asking only:
“Is tryptophan safe?”
a better question is:
“Under what conditions was this particular tryptophan produced, tested, handled, and sold?”
That is a much more sophisticated approach to supplement quality.
Modern manufacturing controls can include procedures for:
- Raw-material qualification
- Ingredient identity testing
- Batch testing
- Contaminant testing
- Process controls
- Equipment sanitation
- Documentation
- Quality investigations
- Product traceability
- Specifications for purity and strength
- Corrective actions when deviations occur
These practices are especially relevant for ingredients produced through fermentation or other complex manufacturing processes.
Why the 1989 Outbreak Changed How People Think About Supplements
The tryptophan story has a broader lesson.
Consumers often think about supplements primarily in terms of the ingredient.
For example:
“It's just an amino acid.”
But a finished supplement is more complicated than its ingredient list.
There is a supply chain behind every capsule or powder.
The ingredient may come from one country, be processed somewhere else, incorporated into a finished product at another facility, packaged by another company, and distributed through multiple channels before reaching a consumer.
At every step, quality can potentially be affected.
The 1989 tryptophan outbreak remains memorable because it showed what can happen when something goes wrong at the ingredient-manufacturing level.
What Happened to Tryptophan After the Restrictions Were Loosened?
Once the regulatory environment changed, L-tryptophan became available again in the U.S. supplement market.
Research also continued.
Importantly, the post-restriction period did not simply reveal an ongoing epidemic of EMS among ordinary tryptophan users.
A later review of the post-epidemic period noted that no new published cases had appeared for years after the ban was lifted, although a sporadic case was subsequently reported and researchers have continued to caution that the original mechanism of EMS was not completely resolved.
This is another reason to avoid two opposite extremes.
It would be wrong to conclude:
“Tryptophan caused the epidemic, therefore all tryptophan is inherently dangerous.”
It would also be wrong to conclude:
“The ban was lifted, therefore every tryptophan product is guaranteed safe.”
The evidence supports a more nuanced position.
The 1989 epidemic was strongly associated with a particular source of L-tryptophan and manufacturing-related impurities, while the FDA later determined that the evidence was insufficient to justify maintaining the broad import restriction.
Does the 1989 EMS Risk Still Matter Today?
It matters primarily as a quality-control and historical safety lesson.
The original outbreak should not be treated as evidence that every modern L-tryptophan supplement will cause EMS.
At the same time, consumers should not interpret the 2005 market reopening as proof that manufacturing quality is irrelevant.
A sensible approach is to pay attention to the quality of the product rather than relying solely on the ingredient name.
If you are researching a tryptophan supplement, consider looking for information about:
Manufacturer transparency
A reputable manufacturer should be willing to identify itself clearly and provide meaningful information about its products and manufacturing practices.
Batch or lot information
Lot numbers make products more traceable and can be useful when investigating quality concerns.
Quality testing
Testing can help verify identity, strength, purity, and the absence of specified contaminants.
Manufacturing standards
Look for manufacturers that describe their quality systems clearly rather than relying entirely on vague phrases such as “premium quality.”
Clear labeling
The label should clearly identify the amount of L-tryptophan per serving and other relevant ingredients.
What Should Consumers Know Before Taking a Tryptophan Supplement?
The regulatory history is only one part of the picture.
L-tryptophan is an essential amino acid found naturally in foods and used by the body in several biochemical pathways.
It is also involved in the production of serotonin and can ultimately contribute to melatonin production.
That biological role is one reason people have historically taken tryptophan supplements for goals involving sleep, mood, or relaxation.
But the existence of a biological pathway does not automatically establish that supplementation will produce a desired health outcome for every person.
More importantly, tryptophan can interact with medications and other substances that affect serotonin or the nervous system.
Anyone considering supplementation should discuss it with a qualified healthcare professional, particularly when taking prescription medications.
Tryptophan and Serotonin: Why the Ingredient Became Popular
Part of the reason tryptophan became a popular supplement is its relationship to serotonin.
In simplified terms, the body can convert L-tryptophan into 5-hydroxytryptophan, commonly known as 5-HTP, which is then involved in serotonin synthesis.
Serotonin is a neurotransmitter involved in numerous physiological processes.
Tryptophan also participates in pathways related to niacin production and protein synthesis.
That broad biological role helps explain why researchers have studied tryptophan for decades.
It also explains why the 1989 crisis was so disruptive.
L-tryptophan was not an obscure industrial chemical. It was a naturally occurring amino acid that had become widely available as a dietary supplement.
Tryptophan vs. 5-HTP: Are They the Same?
No.
L-tryptophan and 5-HTP are chemically related but different compounds.
L-tryptophan is an essential amino acid.
5-HTP is a metabolic intermediate produced from tryptophan and is involved in the pathway toward serotonin.
After L-tryptophan supplements became difficult to obtain in the United States, 5-HTP gained attention as an alternative supplement.
That history sometimes causes people to assume that the two products have identical safety profiles.
They do not.
Their regulatory histories, manufacturing processes, pharmacology, and evidence bases should be evaluated separately.
What the Tryptophan Ban Teaches Us About Supplement Quality
The most useful lesson from the FDA restriction timeline is not simply that tryptophan was once banned.
It is that ingredient safety and manufacturing quality are connected.
A supplement can contain a familiar substance while still presenting problems if the manufacturing process introduces impurities or produces an inconsistent ingredient.
That is why quality systems exist.
For consumers, the takeaway is straightforward:
Do not evaluate a supplement solely by asking whether its active ingredient is natural. Evaluate the entire product and its manufacturing history.
The same principle applies to vitamins, minerals, amino acids, botanical extracts, probiotics, and other dietary supplements.
For people interested in plant-based living and mindful consumer choices, this broader idea of informed purchasing can extend beyond supplements. Brands such as The Dharma Store emphasize ethical and plant-focused lifestyles, including Vegan T-Shirts, but the same basic principle applies: look beyond a label or marketing phrase and consider what stands behind the product.
Why the 2005 Change Still Matters Today
The 2005 cancellation of the import alert is more than an obscure regulatory footnote.
It explains why L-tryptophan, after years of limited availability, became accessible again through the U.S. supplement market.
It also explains why online searches about tryptophan can produce apparently contradictory statements.
One page may say:
“Tryptophan was banned in 1989.”
Another may say:
“The FDA lifted the ban in 2001.”
Another may say:
“The FDA lifted the ban in 2005.”
Each statement is capturing a different part of the timeline.
The most accurate interpretation is:
The major restriction began after the 1989 EMS outbreak; the FDA loosened restrictions in 2001; and the import alert that had continued to restrict foreign-source L-tryptophan was canceled in 2005.
That is why 2005 is commonly treated as the date the tryptophan market fully reopened to imported product.
A Simple Tryptophan Regulatory Timeline
For readers who want the entire history at a glance:
| Year | What happened |
|---|---|
| 1989 | A major EMS outbreak was associated with L-tryptophan-containing dietary supplements. |
| 1989 | FDA issued a nationwide recall involving over-the-counter supplements containing 100 mg or more of L-tryptophan. |
| 1990 | FDA prohibited importation through an L-tryptophan import alert. |
| 1990s | Investigations increasingly connected the outbreak to L-tryptophan from a particular Japanese manufacturer and manufacturing-related impurities. |
| 2001 | FDA loosened some restrictions on marketing L-tryptophan, although import restrictions remained. |
| 2005 | FDA canceled the L-tryptophan import alert, removing the broad import restriction. |
| Today | L-tryptophan is available in the U.S. supplement market, subject to applicable regulatory and manufacturing requirements. |
The timeline demonstrates why describing the entire period as a simple “ban” can leave out important details.
Common Misconceptions About the Tryptophan Ban
Myth: Tryptophan was illegal in the United States from 1989 through 2005
Not quite.
The FDA took major action in 1989, and an import alert effectively removed many foreign sources from the U.S. market. But restrictions changed over time, including a loosening of marketing restrictions in 2001.
Myth: The FDA proved that tryptophan itself causes EMS
The outbreak was strongly associated with L-tryptophan from a particular manufacturer, and investigators identified manufacturing-related impurities.
However, the precise mechanism behind EMS was never reduced to a universally accepted explanation involving one single contaminant.
Myth: The FDA approved all tryptophan supplements in 2005
No.
The key 2005 action was cancellation of the import alert.
That is not the same thing as FDA approval of every tryptophan supplement on the market.
Myth: “Pharmaceutical grade” automatically means FDA approved
No.
The phrase should not be treated as a substitute for understanding the actual manufacturer, specifications, testing, and regulatory status of a product.
Myth: The 2005 change means supplement quality is no longer a concern
The opposite lesson is more useful.
The history demonstrates why ingredient identity, manufacturing controls, and quality testing matter.
What Does the Tryptophan Ban Mean for Today's Consumers?
For someone shopping for L-tryptophan today, the 1989 outbreak can understandably raise a question:
“If this supplement was once associated with a major health crisis, why is it available now?”
The answer lies in the distinction between the ingredient and the manufacturing event.
The regulatory response was driven by an unusually serious outbreak associated with L-tryptophan products from a particular source.
Over time, regulators accumulated more information about the event, restrictions changed, and the FDA eventually determined that the evidence no longer supported maintaining the broad import alert.
That does not eliminate the need for quality control.
Instead, it reinforces it.
When choosing a supplement, consumers should pay attention to the manufacturer, labeling, quality practices, and whether the product is appropriate for their individual circumstances.
If a person is taking medications, has a medical condition, is pregnant or breastfeeding, or is considering tryptophan specifically for sleep or mood concerns, professional medical guidance is especially important.
The Bigger Lesson: A Supplement Is More Than Its Ingredient
The tryptophan story is ultimately a case study in how modern supplement safety works.
An ingredient can be:
- Naturally occurring
- Biologically important
- Widely studied
- Common in foods
and still become the subject of a major regulatory crisis when manufacturing quality fails.
Conversely, a major historical safety event does not necessarily mean the underlying ingredient is permanently unsafe.
Both statements can be true:
The 1989 outbreak was serious and real.
The subsequent evidence did not justify maintaining the same broad import restriction forever.
That is why the 2005 change is best understood not as a simple “ban lifted” moment, but as the endpoint of a long regulatory reassessment.
Frequently Asked Questions About the Tryptophan Supplement Ban
When was the tryptophan supplement ban lifted?
The FDA's major import restriction was lifted in 2005 when the agency canceled its L-tryptophan import alert. Restrictions had already been loosened in 2001, so 2005 is best understood as the end of the broad import restriction rather than the first change since 1989.
Why was tryptophan banned in 1989?
Tryptophan-containing dietary supplements were associated with an outbreak of eosinophilia-myalgia syndrome, a serious illness involving severe muscle pain and elevated eosinophils. Investigations linked the outbreak to L-tryptophan from a particular manufacturer and identified manufacturing-related impurities in the implicated material.
Was tryptophan banned for exactly 16 years?
That depends on what is meant by “banned.” The major restriction began in 1989, while the FDA import alert was issued in 1990. Marketing restrictions were loosened in 2001, but the import restriction remained until 2005. Calling it a 16-year ban is therefore a useful shorthand, but it does not capture every stage of the regulatory timeline.
What changed in 2005 for tryptophan supplements?
The FDA canceled the import alert for L-tryptophan after determining that there was insufficient evidence to continue automatically detaining foreign-source L-tryptophan without physical examination. This allowed imported L-tryptophan intended for dietary supplements to re-enter the U.S. market.
Is pharmaceutical-grade tryptophan FDA approved?
“Pharmaceutical grade” should not automatically be interpreted as “FDA approved.” The 2005 change involved cancellation of the import alert, not blanket FDA approval of every tryptophan product or every ingredient sold under a pharmaceutical-grade label.
Is L-tryptophan safe today?
The 1989 EMS outbreak was associated with contaminated or otherwise altered L-tryptophan from a particular manufacturing source, rather than establishing that all L-tryptophan is inherently unsafe. However, individual products can differ in quality, and L-tryptophan may not be appropriate for everyone. Anyone considering supplementation should discuss it with a qualified healthcare professional, especially when taking medications.
The Bottom Line on the 2005 Tryptophan Market Return
The history behind the tryptophan supplement ban 2005 lifted is more complicated than a simple banned-versus-legal story.
In 1989, a serious outbreak of eosinophilia-myalgia syndrome was linked to L-tryptophan-containing supplements. The FDA responded with a nationwide recall, and an import alert in 1990 effectively kept many foreign sources of L-tryptophan out of the U.S. market.
Investigators eventually connected the outbreak to L-tryptophan produced by a particular manufacturer and identified multiple manufacturing-related impurities in the implicated material.
By 2001, the FDA had loosened some of its restrictions, but the import restriction remained.
Then, in 2005, the FDA canceled the L-tryptophan import alert because the evidence no longer supported continued automatic detention of foreign-source L-tryptophan.
That decision reopened the U.S. market.
The most useful lesson for today's consumer is not that tryptophan was once “dangerous” and is now “safe.” The real lesson is that ingredient quality, manufacturing processes, impurity control, and regulatory oversight all matter.
The 1989 crisis showed what can happen when those systems fail.
The 2005 market return showed how regulatory restrictions can change when the evidence and circumstances change.
And that distinction is still useful whenever you're evaluating a supplement today.
The information in this article is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding dietary or health concerns.